Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cognetivity Neurosciences Ltd C.CGN

Alternate Symbol(s):  CGNSF

Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.


CSE:CGN - Post by User

Post by Swedeprofon Mar 16, 2019 11:16pm
107 Views
Post# 29496929

some more DD on near term potential revenues

some more DD on near term potential revenuesOk, so as Tom mentioned in this video ( https://www.youtube.com/watch?v=TFVK9sfpu4E&feature=youtu.be&fbclid=IwAR0DpaC-0jkOios1Npiv4M8nwpPlmYcljDDfqx1OpAG-st-fn5nb29MhcLI ) there are potential revenue streams. I’ve been told we can expect these revs in Q2 (I believe their Fiscal YE is Jan 31 so Q2 is only weeks away) I believe we see revenues from 2 sources…. First is from the Dacadoo partnership they signed in Nov 2018 https://www.newswire.ca/en/releases/archive/November2018/06/c1814.html

Dacadoo has partnerships with major insurance companies who White Label Dacadoo’s backend software. The platform calculates a real-time Health Score for each user based on 3 key areas: Lifestyle (exercise, nutrition, stress and sleep), Body (biometric measures), and Mind (mental well-being), and motivates users through automated lifestyle coaching, gamification, social features and a reward system. So as a insurance policy holder eats better, sleeps better, exercises more often, takes methods to increase mental health (this is how Cognetivity fits in), they are rewarded with cheaper insurance premiums and the insurance company saves millions of dollars… and Cognetivity will receive a subscription fee from each of these insurance companies!

The second potential revenue stream is from the partnership they signed in Jan 2019 with Dementias Platform UK.I believe how this partnership works is the first chunk of revenue (still DDing how much) is given back to DPUK and after that Cognetivity retains full revenues.
https://www.cognetivity.com/dpuk-partner-announcement-cognetivity/

I’m really looking forward to Q2 as I believe this will be the start of many catalysts:
1. Revenues
2. Validation study completed
3. FDA application approval with 3 months of successful validation study
Bullboard Posts